Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
The FDA and EMA have approved CHOP (Cyclophosphamide + Hydroxydaunorubicin + Prednisone + Vincristine) + Rituximab for first-line treatment of CD20-positive diffuse large B-cell lymphoma. Approval is linked to the rituximab product label, not CHOP as a separate regimen (1). EMA's MabThera is indicated for adult patients with CD20-positive diffuse large B-cell non-Hodgkin lymphoma in combination with CHOP chemotherapy (2)
(1) [Rituxan Plus CHOP Approved for Diffu…